SF2959

Manufacturers interfering with access to 340B drugs prohibition extension
Legislative Session 94 (2025-2026)

Related bill: HF2703

AI Generated Summary

Purpose of the Bill

The purpose of this bill is to ensure continued access to 340B drugs by extending prohibitions preventing drug manufacturers from interfering with such access. The 340B program is a federal initiative that allows eligible health care providers to purchase outpatient drugs at reduced prices, making them more affordable for patients.

Main Provisions

  • The bill aims to repeal the expiration clause of an existing statute, Minnesota Statutes 2024 section 62J.96 subdivision 3, which currently limits the prohibition of manufacturer interference with the 340B drug program.
  • By repealing this clause, the bill seeks to make the protection against interference permanent, beyond the current expiration date of July 1, 2027.

Significant Changes

  • This legislation removes the expiration date, thereby extending indefinitely the statutory restrictions on drug manufacturers from interfering with healthcare providers' access to discount drugs under the 340B program.

Relevant Terms

340B drugs, drug manufacturers, interference, Minnesota Statutes, repeal, expiration.

Bill text versions

Showing the most recent version. There are  2  total versions. You must be logged in  to view additional bill text versions.

Actions

DateChamberWhereTypeNameCommittee Name
March 24, 2025SenateActionIntroduction and first reading
March 24, 2025SenateActionReferred toHealth and Human Services
March 27, 2025SenateActionAuthors added
February 17, 2026SenateActionAuthor stricken
Showing the 5  most recent stages. This bill has 4  stages in total. Log in to view all stages

Citations

You must be logged in  to view citations.

Progress through the legislative process

17%
In Committee

Sponsors

You must be logged in  to view sponsors.

Loading…